Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2018-09-12 Director's Dealing
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice-Gordon 2 pages 248.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and the value of the transaction. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It is not an annual report, earnings release, or any other financial report but specifically a director's dealing notice. Therefore, the correct classification is 'DIRS' (Director's Dealing). The document length is 3664 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or a full report.
2018-09-12 English
Change of Director's Interest Notice-Eck 2 pages 248.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares acquired, disposed, and held before and after the change. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, management discussion, or other report content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3346 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2018-09-12 English
Change of Director's Interest Notice-Cross 2 pages 248.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of interest, and dates of transactions. The document is short (4216 characters) and focuses solely on insider share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). There is no financial performance data or other report content, so it is not an annual or interim report or any other category. Therefore, the correct classification is DIRS.
2018-09-12 English
Lead Antibody Effective in Rare Chronic Kidney Disease 3 pages 33.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited dated 12 September 2018. It reports positive preclinical research results on their lead antibody CAB102 for a rare kidney disease (FSGS). The content focuses on scientific study outcomes, collaboration details, and future regulatory plans such as Orphan Drug application with FDA and EMA. There are no financial statements, earnings data, or management discussion of financial results. The document is a corporate announcement about research progress and regulatory intentions rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about research and development progress and regulatory strategy, which does not fit other specific categories like earnings release, capital update, or management report.
2018-09-11 English
Appendix 3B 13 pages 845.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the number of securities issued, issue price, purpose of the issue, shareholder approvals, and quotation application for additional securities. It references ASX rules and compliance, typical of announcements related to capital raising activities. The content is focused on the announcement and details of a new share issue rather than a full financial report or earnings release. The document length is substantial (15,000 characters), but the content is clearly an announcement of a capital raising event and related securities quotation, not a financial report or regulatory certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-09-11 English
Cleansing Notice 1 page 197.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'CLEANSING NOTICE UNDER SECTION 708A(5)e OF THE CORPORATIONS ACT'. It discusses the issuance and allotment of shares without disclosure under Part 6D.2 of the Corporations Act and compliance with relevant sections. The document is short (1998 characters) and is a regulatory announcement about share issuance compliance, not a full financial report or detailed capital update. It does not contain financial statements or detailed analysis, nor is it a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to share issuance and compliance notices under the Corporations Act.
2018-09-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.